MedPath

BrightPath Biotherapeutics

Ownership
-
Employees
-
Market Cap
-
Website
Introduction

BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Phase 2
Terminated
Conditions
Metastatic NSCLC
First Posted Date
2018-01-31
Last Posted Date
2023-08-08
Lead Sponsor
BrightPath Biotherapeutics
Target Recruit Count
20
Registration Number
NCT03417882
Locations
🇺🇸

St Joseph Hospital of Orange, Orange, California, United States

🇺🇸

University of Colorado Cancer Center, Aurora, Colorado, United States

🇺🇸

Florida Hosptial Cancer Center- AdventHealth, Orlando, Florida, United States

and more 8 locations

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Phase 1
Completed
Conditions
Melanoma
First Posted Date
2016-03-02
Last Posted Date
2018-06-14
Lead Sponsor
BrightPath Biotherapeutics
Target Recruit Count
18
Registration Number
NCT02696356
Locations
🇺🇸

The Christ Hospital Cancer Research, Cincinnati, Ohio, United States

🇺🇸

Providence Health and Services, Providence Portland Medical Center, Portland, Oregon, United States

🇺🇸

University of Pittsburg, Pittsburgh, Pennsylvania, United States

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.